Balentine LLC Sells 191 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Balentine LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 12.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392 shares of the medical research company’s stock after selling 191 shares during the period. Balentine LLC’s holdings in IQVIA were worth $322,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Jag Capital Management LLC boosted its holdings in IQVIA by 0.4% in the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock valued at $2,638,000 after purchasing an additional 49 shares during the period. Laurel Wealth Advisors LLC increased its stake in IQVIA by 1.1% in the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock worth $927,000 after acquiring an additional 50 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of IQVIA by 18.1% in the 3rd quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock valued at $68,000 after acquiring an additional 53 shares in the last quarter. Private Advisor Group LLC grew its holdings in shares of IQVIA by 1.2% during the third quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock worth $948,000 after purchasing an additional 56 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. increased its position in shares of IQVIA by 1.6% in the third quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock worth $702,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of NYSE IQV opened at $226.00 on Thursday. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The company has a 50 day simple moving average of $238.14 and a two-hundred day simple moving average of $228.32. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a market capitalization of $41.18 billion, a price-to-earnings ratio of 30.87, a P/E/G ratio of 2.09 and a beta of 1.52.

Analyst Ratings Changes

A number of research firms have commented on IQV. Evercore ISI cut their price target on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. Robert W. Baird reduced their target price on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a report on Friday, May 3rd. SVB Leerink assumed coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $257.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.